Objective: The aim of this study was to determine the role of smooth muscle 22 (SM22) in aortic dissection (AD) vascular remodeling and its regulatory mechanism on vascular smooth muscle cell function. Methods: Seven patients who underwent surgery for AD with no genetic predisposition and seven organ donors who died from nonvascular diseases were selected. In each aorta sample, the levels of SM22 were detected using immunohistochemistry and Western blot analysis. We inhibited the expression of SM22 with the application of RNA interference in human aortic smooth muscle cells (HASMCs). Cell-counting Kit-8 (Dojindo, Kumamoto, Japan) analyses were used to detect HASMC proliferation. Furthermore, the intracellular calcium concentration was detected using Rhod-2/AM (Dojindo) staining. Results: SM22 was significantly downregulated in the media of AD samples compared with controls (P < .05). In an in vitro study, downregulation of SM22 can significantly promote HASMC proliferation. Our research further revealed that cells treated with nifedipine can inhibit the promoter activity of SM22 downregulation on HASMC proliferation. Intracellular calcium concentration was a significantly varied during the process. Conclusions: SM22 regulates HASMC function activity through intracellular calcium. It presents a downregulation in AD, which might play a potential role in vascular remodeling of AD. (J Vasc Surg 2017;66:875-82.) Clinical Relevance: In the population of China, the prevalence of aortic dissection (AD) is predicted to increase. Vascular smooth muscle cell pathological proliferation has been proven to play a role in AD development and vascular remodeling. This study addresses the role of smooth muscle 22 in mediating vascular smooth muscle cell proliferation, which is regulated by cellular calcium concentration. This study will help illuminate the pathological mechanism of aortic diseases and provide a new insight in research of smooth muscle 22 biological behavior and as a potential therapeutic agent for treatment of AD.
Aortic dissection (AD) is a catastrophic vascular disease with high mortality, severe complications, and increasing incidence. 1, 2 Pathological vascular remodeling plays a key role in the occurrence and development of AD. 3, 4 It is a dynamic process involving human aortic smooth muscle cell (HASMC) apoptosis, proliferation, and corresponding events leading to medial wall thinning. 1, 5 Clarifying the regulatory mechanisms of vascular remodeling is important to gain novel targets for new strategic therapy of AD.
Smooth muscle 22 (SM22) is an actin-binding protein abundant in the smooth muscle cells of vertebrates. 6 It was reported that SM22 facilitates the formation of cytoskeletal structure, which affects the phenotype switch and contractile function of HASMCs. [7] [8] [9] Dong et al reported that high levels of expression of SM22 inhibits cell proliferation via reduction of the response to mitogen stimuli in mouse vascular smooth muscle cells. 10 Shen et al reported that SM22 downregulation in HASMCs can independently promote arterial inflammation through activation of reactive oxygen species-mediated nuclear factor-kB pathways. 11 However, how SM22 regulates vascular remodeling is as important as its role in inflammation of vascular disease, and its role in the AD pathological process is still unclear.
In our previous study we reported that 126 differentially expressed proteins, especially some cytoskeletal proteins, were found between the thoracic AD (TAD) and normal aorta tissue using two-dimensional gel From 12,13 A later study showed that changes in the expression of cytoskeletal proteins such as LIM protein kinases and cofilin might play a role in weakening thoracic aortic medial tissue, as a precondition to TAD. [14] [15] [16] [17] In this study, we further revealed the expression characteristics of SM22 in aortic specimens of AD, and investigated SM22's effects on proliferation of HASMCs. The role of calcium (Ca 2þ ) signal involved in the process was explored and our results provide further understanding of SM22's regulation on vascular remodeling.
METHODS
Patient recruitment and sample collection. Thoracic aortic fragments in the dissected segment were taken from seven patients who underwent surgical repair of TAD. The maximum aorta diameter of these patients was <4.0 cm. Patients with smoking history, Ehlers-Danlos syndrome, Marfan syndrome, aortic aneurysm, other connective tissue disorders, and Ca 2þ receptor blocker intake were excluded. No traumatic aortic injuries were found in these patients. Control thoracic aortic tissues were obtained from seven organ donors who died from nonvascular diseases. Ascending aortic tissue of every specimen was collected within 30 minutes after aorta excision. All of the specimens were rinsed many times with precooled saline solution to remove the blood and mural thrombus adhering to the vascular wall. We clipped a small piece of arterial wall in a tearing dissection and removed adventitia and thrombus immediately using sterile tweezers and eye scissors in a clean Petri dish. All TAD and normal thoracic aorta (NTA) group tissue samples were divided into two parts. One part was cut into approximately 2-mm 3 pieces and placed it in sterile eppendorf tubes. The specimens were then rapidly frozen in liquid nitrogen and stored at 80 C until use. The entire procedure was completed in 10 minutes. The second part was fixed in 4% paraformaldehyde and then embedded in paraffin. This part was also divided into two groups, the dissected group and nondissected group. The dissected group samples were chosen from 1 cm of the distal part of the entry tear. The nondissected aorta samples were obtained from totally "normal"-appearing tissue with no false lumen adjacent to the tear. We did not perform additional surgery beyond standard of care required to obtain these additional specimens. The demographic and clinical characteristics of the included patients and controls are presented in the Western blot assays were repeated three times. After scanning the blots using a flatbed scanner, the band intensities were analyzed using the Image-ProPlus software version 6.0 (Media Cybernetics, Inc, Rockville, Md).
Immunohistochemistry and immunofluorescence analysis. Immunoperoxidase staining for SM22 was performed on 5-mm thick paraffin sections from human aorta samples that were mentioned in the "Patient recruitment and sample collection" section. Immunohistochemical procedures were performed using the Maxvision system (Maxim, Fuzhou, China). Five paraffin-embedded sections of each group were routinely hydrated and then microwave-treated for antigen restoration. Hydrogen peroxide (3%) was used to inactivate endogenous peroxidase for 15 minutes at room temperature. Sections were blocked with nonimmune rat serum for 10 minutes and incubated with rat anti-human SM22 (1:200; Abcam) for 1 hour at room temperature. Maxvision (Maxim) was applied to each slide and then incubated for 15 minutes at room temperature. Liquid A, B, C in the Maxvision kit (Maxim) was mixed in the same volume to perform diaminobenzidine staining. All of these sections were counterstained with hematoxylin, cleared, mounted, and observed using a light microscope. Negative controls were carried out by replacing the primary antibody with nonimmune rabbit serum. Semiquantitative analyses of Cell culture and transfection. Prime HASMCs were purchased from Sciencell (Carlsbad, Calif) and cultured in M199 (Gibco, Grand Island, NY), supplemented with 15% fetal bovine serum (Gibco) and 2% penicillin-streptomycin (Gibco) at 37 C in a humidified atmosphere with 5% CO 2 . Cells in the third to sixth passages were used for all of the experiments. Before each treatment, HASMCs were maintained in serum-free M199 for 24 hours. SM22 lentivirus and vector harboring green fluorescent protein and the control lentivirus (green fluorescent protein lentivirus) were constructed by Obio (Shanghai, China). The short hairpin RNA sequence targeting SM22 were as follows: forward, 5
0 -TGCTGAACAGTCTGGAACATGTCAGTGTTTTGGC CACTGACTGACACTGACATTCCAGACTGTT-3 0 and reverse, 5
0 -CCTGAACAGTCTGGAATGTCAGTGTCA GTCAGTGGCCAAAACACTGACATGTTCCAGACTG TTC-3 0 . The sequences of control short hairpin RNA were as follows: forward 5 0 -tgctgAAATGTACTGCGCGTG GAGACGTTTTGGCCACTGACTGACGTCTCCACG CAGTACATTT-3 0 and reverse, 5 0 -cctgAAATGTACT GCGTGGAGACGTCAGTCAGTGGCCAAAACGTCTC CACGCGCAGTACAT-TTc-3 0 . The lentiviruses for the knockdown of SM22 were provided by Obio. The lentiviruses were diluted in 0.2 mL complete medium at 10 8 transduction units per mL containing hexadimethrine bromide (8 mg/mL, Polybrene; Sigma-Aldrich) and were incubated with the cells with a multiplicity of infection of 60 for 24 hours at 37 C. Next, the medium was then replaced with M199 and the cells were cultured for 48 hours.
Cell proliferation assay. Cell-counting Kit-8 (Dojindo, Kumamoto, Japan) was used to evaluate cell proliferation according to the manufacturer's instructions. HASMCs were seeded in 96-well plates at a density of 5 Â 10 3 cells per well. After cell adhesion, HASMCs were incubated with 1% FBS M199 media for 24 hours. The HASMCs were then treated with lentivirus at the multiplicity of infection of 120 with 15% FBS M199. The medium was replaced every 24 hours. At 0, 1, 2, 3, 4, 5, and 6 days after transfection, 10 mL of Cell-counting Kit-8 (Dojindo) reagent was added to each well, and the cells were further incubated for 4 hours at 37 C. The absorbance was read at 450 nm using a spectrophotometric plate reader. The controls used were HASMCs without lentivirus transfection. The negative controls (vehicle groups) were HASMCs that had been transfected by lentivirus without the SM22 interfering effect. Ca 2D measurement. The preparations were incubated for 30 minutes in zero Ca 2þ saline containing 10 mmol Rhod-2/AM (Dojindo) and 0.03% pluronic F-127 in the dark at 37 C. The preparation was rinsed with Hank's balanced salt solution medium three times. Rhod-2/AM was excited at 557 nm and monitored at wavelengths >580 nm. Fluorescence changes were determined using a confocal laser scanning system (Leica TCS SP5; Leica Microsystems Inc, Buffalo Grove, Ill). Fluorescent intensity for each image was quantified using Image-ProPlus software version 6.0 (Media Cybernetics, Inc).
Statistical analysis. Data were expressed as mean 6 standard error of the mean from three independent experiments. Statistical analysis was performed using Student t-test for two groups of data and using one-way analysis of variance for multiple comparisons when the data were distributed normally. We used a nonparametric test such as c 2 to determine if significant differences existed when the data were not normally distributed. Statistical significance among multiple groups was determined in post hoc analysis (Tukey honest significance difference test). A value of P < .05 was considered to be statistically significant.
RESULTS
SM22 is downregulated in the medial part of the aortic wall in AD. To find the expression characteristics of SM22 in human aorta, we detected the expression of SM22 in AD (seven TAD patients) and their matched NTA tissues (seven organ donors) using Western blot analysis (Fig 1, A) . Remarkable differences were observed: the SM22 expression was significantly lower in the TAD group. Quantitative analysis of Western blot results confirmed the differences between the two groups. Then, immunohistochemistry was performed to detect the distribution of SM22 in human aorta tissues. Immunohistochemical staining with SM22 antibodies was done on cross-sections of the straight part of thoracic aorta. As shown in Fig 1, B , SM22 was mainly distributed in the media of human aorta tissues and the expression of SM22 was decreased in the TAD tissues compared with the NTA tissues (P ¼ .0014). All of these results suggest that SM22 showed a downregulation feature in TAD tissues especially in the medial part of the aortic wall compared with NTA tissues.
HASMCs located in the dissected area showed enhanced proliferation in AD patients. HASMC proliferation is a crucial event of vessel injury, resulting in vascular remodeling diseases such as AD. 18 To investigate the proliferation ability of HASMCs in AD, we performed immunofluorescence analysis using the Ki-67 antibody. We found that the HASMCs in the dissected area of AD patients showed stronger proliferation ability than HASMCs in the NTA group. However, the HASMCs located in any dissected area of AD patients did not represent this characteristic (Fig 2) .
SM22 inhibits HASMC proliferation. To investigate the role of SM22 on human HASMC proliferation, lentiviral vectors containing SM22 gene-silencing effect (LV-SM22-sh) was constructed. After transfecting HASMCs, the result of Western blot analysis showed almost no expression of SM22 in the LV-SM22-sh group. However, noticeable expression of SM22 protein was found in vehicle and control groups and quantitative analysis results confirmed the results (Fig 3, A) . Fig 3, B , from day 2, HASMC growth rates were significantly higher in the LV-SM22-sh group than in the control and vehicle groups. The average optical density value was increased by 1.545-fold at day 2 compared with the vehicle group (Fig 3, C) . However, no significant difference was found between control and vehicle groups. These results suggest that SM22 inhibited HASMC proliferation. Ca 2D signals regulated the effect of SM22 on HASMC proliferation. It was reported that Ca 2þ might implicate in the proliferation of HASMCs. 19, 20 To clarify the role of Ca 2þ signals in the effect of SM22 on HASMC proliferation, we detected cytosolic Ca 2þ concentration using fluorescence assay. 21 As shown in Fig 4, A, the red fluorescence intensity reflects the concentration of cytosolic Ca 2þ . Quantitative measurement showed that the foldchanges in the LV-SM22-sh group was 1.395 6 0.131 compared with the vehicle group, which indicated that Ca 2þ signals might participate in the effect of SM22 on HASMC proliferation (Fig 4, B) .
As seen in
To determine whether Ca 2þ signals regulated the effect of SM22 on HASMCs, we used nifedipine (NIF), a Ca 2þ channel antagonist, to treat HASMCs in 1 mmol/L after transfection with lentivirus. As shown in Fig 4, B, there were no significant differences of cytosolic Ca 2þ fluorescence intensity between the vehicle group without treatment with NIF and the vehicle group treated with NIF. However, in the LV-SM22-sh group, the fold-changes of cytosolic Ca 2þ fluorescence intensity with NIF treatment was 0.642 6 0.254 compared with non-NIF treatment (Fig 4, B) . Meanwhile, using proliferation assay we found that NIF had not affected HASMC proliferation when transfected with vehicle. However, NIF can significantly inhibit HASMC proliferation in the LV-SM22-sh group (Fig 4, C) . Taken together, NIF can inhibit the promoter activity of SM22 downregulation on HASMC proliferation, and this process was realized by mediating the cytosolic Ca 2þ concentration.
DISCUSSION
In our study we first found that was SM22 mainly expressed in the media of human aortic samples. Moreover, significant downregulation of SM22 was found in AD aortic samples compared with normal aortic samples. HASMCs are the main cells that exist in the media of aorta and the proliferation of HASMCs in the dissected area of TAD were significantly higher than in NTA. The weakening of the aortic wall induced by abnormal function of HASMCs has been thought as the initial step of pathologic aorta remodeling. Therefore, it is conceivable that AD vascular remodeling might be due to the downregulation of SM22, by interfering with HASMC function. Actually, pathologic vascular remodeling has been widely found in vascular diseases including AD. In addition, further experiments to reveal whether the expressive discrepancy of SM22 exists in other vascular diseases such as aortic aneurysm will be a focus of future study. It has been reported that cells from AD tissues seem to proliferate faster than normal aorta tissues and the genes that participate in proliferation showed an elevated level of expression. 22 Abnormal proliferation of HASMCs can affect the stability of vascular media structure and function, which might be the main cause of pathologic vascular remodeling and vascular disease occurrence. 23 Our study confirmed the abnormal proliferation of HASMCs in AD especially in the dissected area. To our knowledge, cytokines such as platelet derived growth factor have been reported to stimulate HASMC proliferation, which further participates in vascular disease. 24 Phenotype modulation of HASMCs also has been thought as an incitant of its abnormal proliferation. 25 However, HASMCs phenotype marker protein biological behavior on HASMC proliferation has been seldom reported. In our study, SM22 was downregulated in HASMCs by RNA interfere and the proliferation of HASMCs was significantly promoted. SM22 itself might be the protective factor during the process. Ca 2þ is one of the intracellular second messengers. Using Ca 2þ fluorescence intensity detection in our study, we observed that SM22 downregulation not only did promote activity on HASMC proliferation but also we observed a marked increase of cytosolic Ca 2þ . This indicates that the Ca 2þ signal might participate in SM22 regulation of HASMC proliferation. Extracellular medium influx and the release from intracellular stores are two main pathways that regulate cytosolic Ca 2þ concentration. 26, 27 Extracellular medium influx was mainly mediated by the Ca 2þ channel located in membrane. L-type voltage-depended Ca 2þ channels (VDCC) is the uppermost Ca 2þ channel and NIF can specially block it. Our results showed that NIF treatment had no effect on static status of HASMC proliferation and cytosolic Ca 2þ concentration. However, NIF triggered the inhibition of the increase of HASMC proliferation and cytosolic Ca 2þ concentration, which were induced by SM22 downregulation. Accumulating evidence suggests that cytosolic Ca 2þ and VDCC might play essential roles in SM22's regulation on HASMC proliferation. In our study, we further revealed the pivotal role of the Ca 2þ signal in pathologic aorta remodeling. Meanwhile, the recognition of VDCC's function in this process provides a novel intervention target for further research on the mechanism of SM22 regulation on AD vascular remodeling and the VDCC's change during the AD pathological process needs to be further researched. It worth noting that NIF is one of the most important medicines in clinical therapy of AD. NIF has been considered to control blood pressure through enhancing the contractility of HASMCs, 28 which can alleviate the rupture risk of aorta in AD. 29 Our study showed the inhibition effect of NIF on HASMC abnormal proliferation, which was induced by SM22 downregulation, and this effect might be realized by VDCC suppression. We presume that these findings will be a critical supplement to the pharmacological therapy of AD. Inhibition of HASMC abnormal proliferation might be a protectable process of the AD pathological process; NIF not only controls blood pressure but also inhibits the abnormal proliferation of HASMCs in AD. Therefore, our research will provide a promising strategy for therapy in AD.
Despite that our results clearly showed an involvement of SM22 in AD, the exact mechanisms involved in the regulation of abnormal HASMC proliferation after downregulation of SM22 remain unclear. In fact, although SM22 expression is obviously downregulated in TAD compared with NTA, limited by our samples, there are still some factors such as age that need to be considered. Apoptosis of HASMCs also play a role in AD. In fact, when SM22 was downregulated in HASMCs, we did not find any effect on HASMC apoptosis. However, we do not exclude the possibility that SM22 has a regulatory role on HASMC apoptosis involved in AD. Further study should be done on this subject.
CONCLUSIONS
The present study describes AD tissue-specific expression of SM22 in detail, to our knowledge, for the first time. Combined with HASMC function, and variation of features in pathologic vascular remodeling, we identified SM22's role in regulating HASMC proliferation and further revealed the regulatory role of the Ca 2þ signal in this process. Overall, these results will be conducive to illuminate the pathologic mechanism in aortic diseases, and provide new insight in researching the biological behavior of SM22, as potential therapeutic agent for treatment of AD. 
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